NanoViricides, Inc. Common Stock (NNVC)

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda, stating the oral drug candidate could offer a differentiated approach if proven effective against the virus strain. The company emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda.

NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, highlighting continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo, where regulatory approval for the trial has already been obtained. The company also outlined progress in its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted subsequent to the quarter and additional applications targeting MPox and smallpox.

NanoViricides, Inc. (NYSE American: NNVC) announced a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds through the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants will carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions.

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced it has entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 1,333,334 million common shares (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase 1,333,334 common shares for gross proceeds of approximately US$2 million in a registered direct offering (the "Offering"). The common shares are being sold in combination with an accompanying full warrant (with each whole warrant being exercisable into one common share of the Company). Each whole warrant has an exercise price of US$1.75 per share and will expire three years from the date of issuance.

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2026 with the Securities and Exchange Commission (SEC) on Thursday, May 14, 2026. The report can be accessed at the SEC website by searching for the Company (https://www.sec.gov/edgar/browse/?CIK=1379006&owner=exclude) .

NanoViricides, Inc. (NYSE American: NNVC) highlighted the potential need for broad-spectrum antiviral treatments following the recent Andes hantavirus incident aboard a cruise ship, pointing to its clinical-stage antiviral candidate NV-387 as a potential therapeutic platform for emerging viral threats. The company said NV-387 has completed a Phase I safety and tolerability trial in healthy volunteers and has demonstrated effectiveness in animal models involving multiple viral lung infections, including coronaviruses, RSV, influenza, monkeypox and measles, as it advances development of a platform designed to target a broad range of pathogenic viral infections.

SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 in light of the recent Andes hantavirus incident on a cruise ship that has led to a flurry of worldwide activity to effectively quarantine the ship MV Hondius and trace passengers' contacts in an effort to prevent a potential global epidemic.

NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the D. Boral Capital Global Conference on May 7, 2026, at The Plaza Hotel in New York City, where Anil R. Diwan, Ph.D., president and executive chairman, will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET.

NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of measles, providing potential incentives including tax credits, fee exemptions and market exclusivity. The company said the designation supports regulatory advancement of NV-387, a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles and is being developed to address rising global outbreaks.

SHELTON, CT / ACCESS Newswire / May 4, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that its clinical stage, broad-spectrum, antiviral drug NV-387 has been granted an "Orphan Drug Designation" (ODD) by the US FDA Office of Orphan Products Development (OOPD).

NanoViricides, Inc. (NYSE American: NNVC) announced that its antiviral drug candidate NV-387 may address the growing global measles outbreak, citing recent case surges including more than 18,000 suspected infections in Bangladesh and rising cases in the United States. The company stated that NV-387 has demonstrated safety in Phase I clinical trials and efficacy in animal models, positioning it as a potential therapeutic complement to vaccination by reducing transmission and treating infected patients, particularly among vulnerable populations, while also noting plans to pursue orphan and rare pediatric disease designations with the FDA.

SHELTON, CT / ACCESS Newswire / April 21, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments that its drug candidate NV-387 is the weapon necessary for combatting growing cases of deadly measles worldwide.

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals, announced it has filed an application with the U.S. FDA for Rare Pediatric Disease Drug designation for NV-387 as a treatment for measles. The application, which follows a previously submitted orphan drug designation filing, could make the company eligible for a Priority Review Voucher upon approval, supporting regulatory advancement of NV-387 as a potential treatment in a market where no approved measles therapies currently exist.

SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.

NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA.

SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo (DRC).

NanoViricides, Inc. (NYSE American: NNVC) announced that it will present at NIBA’s 152nd Investment Conference in Fort Lauderdale on March 12, where President and Executive Chairman Anil R. Diwan will outline progress on the company’s broad-spectrum antiviral platform. The company also reported that manufacturing of its NV-387 Oral Gummies drug product has been completed in preparation for patient dosing once clinical sites are ready, as the therapy advances toward a Phase II trial for monkeypox in the Democratic Republic of Congo following a successful Phase I safety study in healthy volunteers.

SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, Florida.

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation for NV-387 as a treatment for MPox with the U.S. FDA Office of Orphan Products Development. If granted, the designation would provide incentives including tax credits for qualified clinical trials, exemption from certain user fees and potential seven years of market exclusivity following approval. The company highlighted ongoing global MPox concerns, limited therapeutic options and challenges associated with existing smallpox antivirals such as TPOXX(R) and TEMBEXA(R), noting continued viral mutations and the need for an effective therapeutic solution.

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for Orphan Drug Designation (ODD) for "NV-387 as a Treatment for MPox" with the US FDA Office of Orphan Products Development (OOPD).

In a strategic regulatory move that could accelerate its path to market, NanoViricides, Inc. (NYSE American: NNVC) announced that it has filed for Orphan Drug Designation with the FDA for NV-387, its experimental measles treatment—a timely development as the country grapples with a dramatic resurgence of the once-rare disease.

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral developer, announced that it has filed an application with the U.S. Food and Drug Administration Office of Orphan Products Development for Orphan Drug Designation for NV-387 as a treatment for measles. If granted, the designation would make the Company eligible for incentives including tax credits for qualified clinical trials, exemptions from certain FDA user fees, and up to seven years of market exclusivity following approval, supporting the regulatory development of NV-387 amid rising measles cases in the United States and globally.

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD).

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics. He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase I clinical trial with no reported adverse events. Dr. Diwan added that a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance, positioning the candidate as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.